← Back to Search

Antiparasitic Agent

Suramin for Acute Kidney Injury

Phase 2
Waitlist Available
Research Sponsored by Rediscovery Life Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 days
Awards & highlights

Study Summary

This trial will test if the drug suramin can prevent kidney disease from progressing to stage III or if patients will need dialysis. The study is double-blind, meaning that neither the patients nor the doctors will know who is receiving the drug or the placebo.

Who is the study for?
Adults with early-stage acute kidney injury (AKI) who haven't responded to a diuretic called furosemide are eligible. They must not have severe liver issues, be on multiple blood pressure medications, or have certain infections like HIV or COVID-19. A negative pregnancy test is required for women of childbearing age.Check my eligibility
What is being tested?
The study is testing Suramin against a placebo in patients with AKI to see if it can prevent worsening to Stage III AKI or the need for dialysis. Participants will be randomly assigned to receive either Suramin or a placebo without knowing which one they're getting.See study design
What are the potential side effects?
While specific side effects of Suramin in this trial context aren't listed, common ones may include nausea, vomiting, fatigue, and possible allergic reactions. The severity and type of side effects can vary from person to person.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To evaluate and compare the efficacy of a single 3.0 mg/kg infusion of suramin versus placebo in subjects with diuretic unresponsive AKI

Side effects data

From 2016 Phase 1 & 2 trial • 10 Patients • NCT02508259
100%
Rash
40%
Upper respiratory tract infection (URI)
40%
Hyperactivity
20%
Hypoglycemia
20%
Vomiting
20%
Headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
Suramin
Saline (Placebo)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: SuraminExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Suramin
2012
Completed Phase 3
~520

Find a Location

Who is running the clinical trial?

Rediscovery Life SciencesLead Sponsor

Media Library

Suramin (Antiparasitic Agent) Clinical Trial Eligibility Overview. Trial Name: NCT04496596 — Phase 2
Acute Kidney Injury Research Study Groups: Suramin, Placebo
Acute Kidney Injury Clinical Trial 2023: Suramin Highlights & Side Effects. Trial Name: NCT04496596 — Phase 2
Suramin (Antiparasitic Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04496596 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available slots for volunteer participants in this study?

"Affirmative. As evidenced by the clinicaltrials.gov page, this research is actively recruiting volunteers for participation - 58 participants from 9 locations to be exact. The trial was first posted on November 13th 2020 and has been updated most recently on December 16 2021."

Answered by AI

Has Suramin been granted authorization from the FDA?

"Owing to the limited evidence of efficacy, suramin is assigned a safety rating of 2. Clinical data does exist in support of its safety profile however."

Answered by AI

Does this experiment represent a groundbreaking approach to research?

"At present, just one ongoing trial of Suramin is taking place in 9 cities across 1 country. Rediscovery Life Sciences first launched their study on the drug back in 2020 and completed Phase 2 approvals with 58 participants involved. Since then, 18333 trials have been successfully concluded."

Answered by AI

Are there extensive facilities conducting this clinical experiment throughout North America?

"The list of clinical trial sites includes - but is not limited to - the University of Kentucky in Lexington, the University of New mexico Health Science Center in Albuquerque and Southeast Renal Research Institute at Chattanooga."

Answered by AI

How many participants are enrolled in this research endeavor?

"Affirmative. Clinicaltrials.gov attests that this medical research project, which was posted on November 13th 2020, is actively recruiting. Approximately 58 patients are sought from 9 trial sites."

Answered by AI

What other investigations have taken place using Suramin as a potential treatment?

"Currently, one trial studying Suramin is in progress with zero trials at the Phase 3 stage. Most of such research projects are situated in Little Rock, Arkansas while nine other medical centres are also running studies related to this medication."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study of Suramin in Subjects With Furosemide-Resistant AKI
2020. "Study of Suramin in Subjects With Furosemide-Resistant AKI". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04496596.
~15 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top